ENTITY
Shanghai Henlius Biotech

Shanghai Henlius Biotech (2696 HK)

317
Analysis
Health Care • China
Shanghai Henlius Biotech, Inc develops and produces drugs. The Company develops and produces monoclonal antibody biosimilar drugs, bio betters, novel monoclonal antibodys, and other drugs. Shanghai Henlius Biotech throughout China.
more
•02 Dec 2024 01:49

Merger Arb Mondays (02 Dec) - Shinko, WealthNavi, AVJennings, SG Fleet, Latin Res, Get Nice, GA Pack

This week, the highest gross spreads are WealthNavi (43.6%), Henlius (14.4%), Shinko Electric (12.8%), Get Nice Financial (12.8%), Arcadium Lithium...

Logo
708 Views
Share
•01 Dec 2024 09:42

China Healthcare Weekly (Dec.1)- 2024 NRDL Result, Expectation Gap for Biotech, Henlius' Wide Spread

​2024 NRDL results released, posing new challenges. Expectation gap for biotech in HK provides opportunities. Henlius' privatization progress is...

Logo
847 Views
Share
•01 Dec 2024 06:30

Last Week in Event SPACE: Keisei Electric Railway, Vitasoy, NEC Network, ESR Group

It’s Sunday! Pour yourself a coffee, grab a comfortable seat, and sift through a brief summary of insights on various events discussed during the...

Logo
603 Views
Share
bullish•Seven & I Holdings
•01 Dec 2024 06:25

Mostly) Asia-Pac M&A: SG Fleet, Shandong Hi-Speed New Energy, HPI, Capitol Health, Henlius, 7 & I

This insight provides a summary of gross/annualised spreads (on deals discussed on Smartkarma) across Asia-Pacific as at the last trading date, and...

Logo
591 Views
Share
•25 Nov 2024 09:52

Henlius (2696 HK): The Spread Should Narrow After NDRC Approval

Currently trading at an excessive gross/annualised spread of 21.5%/39.6%, assuming late-June payment. I'd get involved here. I'd pay up to HK$22.70...

Logo
627 Views
Share
x